Using machine learning techniques to predict hospital admission at the emergency department

TL;DR

This study develops machine learning models using common blood biomarkers and patient data to predict hospital admission in emergency department patients, aiming to improve decision-making efficiency.

Contribution

The paper introduces a set of ML algorithms trained on routine biomarkers for hospital admission prediction, demonstrating acceptable accuracy and potential clinical utility.

Findings

Models achieved F-measure 0.679-0.708

ROC Area 0.734-0.774

Low-cost, accessible prediction tool

Abstract

Introduction: One of the most important tasks in the Emergency Department (ED) is to promptly identify the patients who will benefit from hospital admission. Machine Learning (ML) techniques show promise as diagnostic aids in healthcare. Material and methods: We investigated the following features seeking to investigate their performance in predicting hospital admission: serum levels of Urea, Creatinine, Lactate Dehydrogenase, Creatine Kinase, C-Reactive Protein, Complete Blood Count with differential, Activated Partial Thromboplastin Time, D Dimer, International Normalized Ratio, age, gender, triage disposition to ED unit and ambulance utilization. A total of 3,204 ED visits were analyzed. Results: The proposed algorithms generated models which demonstrated acceptable performance in predicting hospital admission of ED patients. The range of F-measure and ROC Area values of all eight evaluated algorithms were [0.679-0.708] and [0.734-0.774], respectively. Discussion: The main advantages of this tool include easy access, availability, yes/no result, and low cost. The clinical implications of our approach might facilitate a shift from traditional clinical decision-making to a more sophisticated model. Conclusion: Developing robust prognostic models with the utilization of common biomarkers is a project that might shape the future of emergency medicine. Our findings warrant confirmation with implementation in pragmatic ED trials.